Special Issue "Advances in Pediatric Formulations"

A special issue of Children (ISSN 2227-9067).

Deadline for manuscript submissions: 15 September 2021.

Special Issue Editor

Dr. Hassan Almoazen
E-Mail Website
Guest Editor
College of Pharmacy, University of Tennessee Health Science Center, 881 Madison Ave, Rm 661 Memphis, TN 38163, USA
Interests: paediatric formulations; enhancing drug solubility; enhancing drug stability; enhancing drug permeability; design of prodrugs

Special Issue Information

Dear Colleagues,

In the past several years, we have witnessed a remarkable interest and encouragement from the Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the National Institute of Health (NIH) towards pediatric formulations. Despite all incentives offered by the above governmental agencies, though, there are still many therapeutic agents lacking pediatric-friendly drug delivery systems.

One of the major challenges that academic scientists have traditionally faced in this area is lack of funding and support for this line of research, with most of the governmental funding going towards the advancement of novel drug delivery systems with little impact on the pediatric population. Many novel and targeted drug delivery systems have faced many challenges when it comes to translation into pediatric patients. Some of these challenges include excipients’ toxicity and limited stability and shelf life, but the major limitation has been pursuing the most invasive drug delivery route (parenteral delivery). It is generally accepted that translational drug delivery systems are friendlier, easier to use and can impact the safety and prosperity of children as well as profoundly prolong their adherence to medication when designed properly. Due to the lack of funding in this area, however, very few academician scientists have taken on the challenge and pursued this area for a career.

The purpose of this Special Issue of Children is to draw attention to the importance of pediatric formulations and to provide scientists with a platform to publish their novel research work in this area. 

This Special Issue seeks novel topics pertaining to advances in pediatric formulations. Original research as well as reviews will be considered for publication.

We look forward to receiving your contributions.

Kind regards,

Dr. Hassan Almoazen
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Children is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pediatric formulations
  • drug stability
  • drug solubility
  • drug permeability
  • prodrug design
  • sublingual absorption
  • oral absorption
  • transdermal delivery
  • pulmonary delivery
  • fast dissolving tablets
  • fast dissolving films
  • microneedles
  • oral niosomes

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

Review
An Update on Pharmaceutical Strategies for Oral Delivery of Therapeutic Peptides and Proteins in Adults and Pediatrics
Children 2020, 7(12), 307; https://doi.org/10.3390/children7120307 - 19 Dec 2020
Cited by 4 | Viewed by 1605
Abstract
While each route of therapeutic drug delivery has its own advantages and limitations, oral delivery is often favored because it offers convenient painless administration, sustained delivery, prolonged shelf life, and often lower manufacturing cost. Its limitations include mucus and epithelial cell barriers in [...] Read more.
While each route of therapeutic drug delivery has its own advantages and limitations, oral delivery is often favored because it offers convenient painless administration, sustained delivery, prolonged shelf life, and often lower manufacturing cost. Its limitations include mucus and epithelial cell barriers in the gastrointestinal (GI) tract that can block access of larger molecules including Therapeutic protein or peptide-based drugs (TPPs), resulting in reduced bioavailability. This review describes these barriers and discusses different strategies used to modify TPPs to enhance their oral bioavailability and/or to increase their absorption. Some seek to stabilize the TTPs to prevent their degradation by proteolytic enzymes in the GI tract by administering them together with protease inhibitors, while others modify TPPs with mucoadhesive polymers like polyethylene glycol (PEG) to allow them to interact with the mucus layer, thereby delaying their clearance. The further barrier provided by the epithelial cell membrane can be overcome by the addition of a cell-penetrating peptide (CPP) and the use of a carrier molecule such as a liposome, microsphere, or nanosphere to transport the TPP-CPP chimera. Enteric coatings have also been used to help TPPs reach the small intestine. Key efficacious TPP formulations that have been approved for clinical use will be discussed. Full article
(This article belongs to the Special Issue Advances in Pediatric Formulations)
Show Figures

Figure 1

Back to TopTop